Why Denali’s recent earnings and shelf registration matter for shareholders

Denali Therapeutics (DNLI) has drawn fresh attention after reporting a wider fourth quarter and full year 2025 loss alongside a new US$200.7 million shelf registration for common stock, raising questions about dilution and funding plans.

For the fourth quarter, Denali reported a net loss of US$128.55 million, with basic and diluted loss per share from continuing operations of US$0.73, compared with US$0.67 a year earlier.

For the full year to 31 December 2025, the company posted a net loss of US$512.54 million. Basic and diluted loss per share from continuing operations were US$2.97, versus US$2.57 in the prior year.

On the same date as the earnings release, Denali filed a shelf registration covering up to US$200.73 million of common stock, or 9,370,929 shares, described as an ESOP related offering.

For you as a shareholder or potential investor, the combination of a larger reported loss and additional registered shares puts the focus on capital needs, potential dilution, and how management plans to fund its neurodegenerative and lysosomal storage disease programs.

Denali’s share price has eased in recent weeks, with a 7 day share price return of 6.24% and a 30 day share price return of 6.59% around US$19.69. However, the year to date share price return of 21.02% and 1 year total shareholder return of 31.71% still point to positive momentum over a longer stretch.

If this earnings update has you reassessing risk and reward in biotech, it might be a good moment to look across the sector and see what else is working. You could start with 32 healthcare AI stocks as a curated set of ideas to compare.

With Denali trading around US$19.69, showing a 21.02% year-to-date return and an indicated 17% discount to estimated fair value, is this a genuine buying opportunity or is the market already factoring in future growth?

Price to book of 3.1x, is it justified?

At a last close of $19.69, Denali trades on a P/B of 3.1x, which screens as expensive versus the broader US biotech industry, but lower than its closer peer set.

P/B compares a company’s market value to the book value of its net assets. It is often used for early stage or loss making biotechs where earnings are not yet a useful reference point. For Denali, that 3.1x multiple suggests investors are paying a premium over the company’s accounting equity for its drug development pipeline and expected future cash flows, even though it currently reports a loss and has minimal reported revenue.

Relative to the wider US biotechs group at 2.7x, the 3.1x P/B implies the market is assigning Denali a richer valuation than the average, likely reflecting its portfolio in neurodegenerative and lysosomal storage diseases and forecasts for fast revenue growth of 50.9% per year. Compared with a peer average P/B of 10.6x, however, the same 3.1x multiple looks restrained, which shows investors are pricing in some potential upside but not to the same degree as many peers.

Result: Price to book of 3.1x (ABOUT RIGHT)

However, you still need to weigh clinical or regulatory setbacks in Denali’s pipeline, as well as any future equity raises that could dilute your stake.

Another view on value

The P/B of 3.1x paints one picture, but our DCF model adds a different angle. With Denali at US$19.69 and our estimated future cash flow value at US$23.79, the shares screen as undervalued. If earnings stay weak, will sentiment or cash flow expectations be the main driver of the next move?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of losses, valuation signals and funding questions leaves you torn, do not wait for consensus. Instead, check the balance yourself with 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you are serious about tightening up your portfolio after reading this, do not stop at one company; use the tools that help you compare options quickly.

• Target potential value opportunities by scanning our 50 high quality undervalued stocks and see which companies currently trade below their assessed worth.
• Prioritise resilience with the 66 resilient stocks with low risk scores, so you can quickly spot businesses that score well on stability and risk metrics.
• Hunt for lesser known opportunities using the screener containing 24 high quality undiscovered gems that highlight companies with solid fundamentals but limited market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.